P1.16-07 Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients With High PD-L1 Expression in Singapore

Journal of Thoracic Oncology- United States

doi 10.1016/j.jtho.2018.08.976

Full Text

Abstract

Available in

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Cost Effectiveness of PD-L1-Based Test-And-Treat Strategy With Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

PharmacoEconomics - Open

Health Policy

Pharmacology

2019

English

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology

Italian

Pcn178 - Cost-Effectiveness of Pembrolizumab as Second-Line Treatment for Patients With Advanced Urothelial Cancer in France

English

Cn5 - Cost-Effectiveness of Pembrolizumab Versus Standard-Of-Care Chemotherapies for First-Line Treatment of Pd-L1 Positive (≥50%) Metastatic Non-Small Cell Lung Cancer in France

English

Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

Cancer Immunology, Immunotherapy

English

P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC With PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

Journal of Thoracic Oncology

English

P1.01-16 First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 Positive NSCLC: A Network Meta-Analysis of Randomized Trials

Journal of Thoracic Oncology

English

P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Journal of Thoracic Oncology

English

Pcn34 - Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-Squamous NSCLC – A Network Meta-Analysis

English

Amanote Research

P1.16-07 Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients With High PD-L1 Expression in Singapore

Journal of Thoracic Oncology- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Cost Effectiveness of PD-L1-Based Test-And-Treat Strategy With Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Pcn178 - Cost-Effectiveness of Pembrolizumab as Second-Line Treatment for Patients With Advanced Urothelial Cancer in France

Cn5 - Cost-Effectiveness of Pembrolizumab Versus Standard-Of-Care Chemotherapies for First-Line Treatment of Pd-L1 Positive (≥50%) Metastatic Non-Small Cell Lung Cancer in France

Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC With PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

P1.01-16 First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 Positive NSCLC: A Network Meta-Analysis of Randomized Trials

P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Pcn34 - Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-Squamous NSCLC – A Network Meta-Analysis